Atavistik Bio, a biotechnology company committed to discovering the next generation of precision allosteric therapeutics inspired by the body’s natural regulators, announced that it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant unmet medical needs.
Under the terms of the collaboration, Atavistik Bio will leverage its proprietary AMPS platform to identify novel allosteric binders against two undisclosed, targets selected by Pfizer. At the completion of the research period, Pfizer will have the option to license the programs. The financial terms of the collaboration are undisclosed.
“Allostery holds the key to targeting disease-causing proteins and delivering highly selective, better tolerated, and more effective therapies. We’re excited to collaborate with Pfizer to harness the tremendous promise of allostery to advance the opportunity for therapeutic innovations for patients in need,” said Bryan Stuart, CEO of Atavistik Bio. “Our internal pipeline has been enabled by our ability to identify novel, functional allosteric binding pockets that allow us to rapidly progress novel chemical matter. We look forward to applying the efficiency and productivity of our platform to our collaboration with Pfizer as we simultaneously advance our internal pipeline of precision oncology small molecule therapies.”
Atavistik Bio’s proprietary AMPS platform is a highly integrated discovery engine that combines proprietary computational and experimental techniques to rapidly unlock functional cryptic pockets across a broad range of target classes. By leveraging insights from these novel allosteric chemical starting points, the platform enables the design of small molecules against historically challenging targets. Our highly integrated team and automated data infrastructure makes rapid iteration and progression of chemistry possible, while the versatility of its platform allows the company to accelerate the development of groundbreaking medicines across any therapeutic area.
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology.
|